A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma

Cancer

Volumn 94, Issue 2, 2002, Pages 299-304

  Bajetta, Emilio ^a   Procopio, Giuseppe ^a   Ferrari, Leonardo ^a   Martinetti, Antonia ^a   Zilembo, Nicoletta ^a   Catena, Laura ^a   Alú, Massimiliano ^a   Della Torre, Silvia ^a   Alberti, Daniele ^b   Buzzoni, Roberto ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Respiratory Clinical Research   (Italy)

Author keywords

Advanced breast carcinoma; Hormone therapy; Insulin like growth factor 1.; Octreotide pamoate; Tamoxifen

Indexed keywords

OCTREOTIDE; PEPTIDE DERIVATIVE; TAMOXIFEN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE PAIN; BREAST CARCINOMA; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT INDICATION; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DELAYED-ACTION PREPARATIONS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MENOPAUSE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; OCTREOTIDE; PLACEBOS; PROSPECTIVE STUDIES; SURVIVAL RATE; TAMOXIFEN; TREATMENT OUTCOME;

EID: 0037080274     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10239     Document Type: Article

References (28)

1. Prognostic factors in elderly women with metastatic breast cancer treated with tamoxifen: An analysis of patients entered in four prospective clinical trials
2. A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma
3. Plasma insulin growth factor I (IGF-I) concentration in human breast cancer
4. Characterization of insulin-like growth factor I (IGF-I) receptors of human breast cancer cells
5. Octreotide
6. Insulin-like growth factors and cancer
7. The relationship between somatostatin, epidermal growth factor and steroid hormone receptors in breast cancer
8. Rationale for combined antiestrogen-somatostatin analogue therapy of breast cancer
9. The role of somatostatin and its analogs in the diagnosis and treatment of tumors
10. Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients
11. Appendix A grading of toxicity
12. Growth regulation of human breast carcinoma occurs through regulated growth factor secretion
13. Characterization of estrogen responsive transforming activity in human breast cancer cell lines
14. Somatostatin analogue octreotide enhances the antineoplastic effect of tamoxifen and ovariectomy on 7,12-dimethylbenz (a)anthracene-induced rat mammary carcinomas
15. Biological and clinical evaluation of lanreotide (BIM 23014), a somatostatin analogue, in the treatment of advanced breast cancer. A pilot study by the ITMO Group. Italian Trials in Medical Oncology
16. Oncological applications of somatostatin analogues
17. Octerotide long-acting release (LAR): A review of its pharmacological properties and therapeutic use in the management of acromegaly
18. Therapeutic benefit of lanreotide-tamoxifen combination in the treatment of breast tumors
19. Mechanisms of antineoplastic action of somatostatin analogues
20. Octreotide as first-line treatment for women with metastatic breast cancer
21. Somatostatin analogs inhibit angiogenesis in the chick chorioallantoic membrane
22. Preclinical studies on the anticancer activity of the somatostatin analogue octreotide (SMS 201-995)
23. Some practical aspects of the interim monitoring of clinical trial
24. Interim monitoring of clinical trials based on long-term binary endpoints
25. Bayesian monitoring of phase II trials in cancer chemoprevention
26. Phase 3 trial of SMS 201-995 pa LAR (SMS PA LAR) and continuous infusion (CI) 5-FU in unresectable stage II, III, and IV pancreatic cancer
27. Phase 3 trial of SMS 201-955 pa LAR (SMS pa LAR) vs. placebo in unresectable stage II, III and IV pancreatic cancer
28. Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients